Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Curtin

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Pathology, Research and Practice|August 25, 2015
Successful treatment of both double minute of C-MYC and BCL-2 rearrangement containing large B-cell lymphoma with subsequent unfortunate development of therapy-related acute myeloid leukemia with t(3;3)(q26.2;q21)John C Nguyen, Melanie J Kubik, H Elizabeth Broome, et al.
Human Pathology|June 17, 2011
t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemiaHuan-You Wang, John A Thorson, H Elizabeth Broome, et al.
Haematologica|September 21, 2004
Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisisJose F Leis, Steven L Primack, Susan E Schubach, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|February 24, 2001
An EEG severity index of traumatic brain injuryR W Thatcher, D M North, R T Curtin, et al.
Bone Marrow Transplantation|September 5, 2002
Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosisB M Hayes-Lattin, P T Curtin, W H Fleming, et al.
Leukemia & Lymphoma|May 27, 2004
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571)Jose F Leis, Daniel E Stepan, Peter T Curtin, et al.
The Journal of Infectious Diseases|July 29, 2000
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 diseaseS Emery, W B Capra, D A Cooper, et al.
Leukemia Research|June 6, 2025
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)Brian A Jonas, Samantha C Fisch, Peter T Curtin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 19, 2012
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow TransplantationPaul J Martin, J Douglas Rizzo, John R Wingard, et al.
Blood|August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Pathology, Research and Practice|August 25, 2015
Successful treatment of both double minute of C-MYC and BCL-2 rearrangement containing large B-cell lymphoma with subsequent unfortunate development of therapy-related acute myeloid leukemia with t(3;3)(q26.2;q21)John C Nguyen, Melanie J Kubik, H Elizabeth Broome, et al.
Human Pathology|June 17, 2011
t(4;22)(q12;q11.2) involving presumptive platelet-derived growth factor receptor A and break cluster region in a patient with mixed phenotype acute leukemiaHuan-You Wang, John A Thorson, H Elizabeth Broome, et al.
Haematologica|September 21, 2004
Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisisJose F Leis, Steven L Primack, Susan E Schubach, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences|February 24, 2001
An EEG severity index of traumatic brain injuryR W Thatcher, D M North, R T Curtin, et al.
Bone Marrow Transplantation|September 5, 2002
Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosisB M Hayes-Lattin, P T Curtin, W H Fleming, et al.
Leukemia & Lymphoma|May 27, 2004
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571)Jose F Leis, Daniel E Stepan, Peter T Curtin, et al.
The Journal of Infectious Diseases|July 29, 2000
Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 diseaseS Emery, W B Capra, D A Cooper, et al.
Leukemia Research|June 6, 2025
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)Brian A Jonas, Samantha C Fisch, Peter T Curtin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 19, 2012
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow TransplantationPaul J Martin, J Douglas Rizzo, John R Wingard, et al.
Blood|August 12, 2006
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo, Richard M Stone, Mark L Heaney, et al.
Pageof 7